Compare Incyte Corporation (INCY) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Vanguard High Dividend Yield ETF — how do they compare? Incyte Corporation trades at $118 (market cap $23.11B), while Vanguard High Dividend Yield ETF trades at $160.41. Which is the better fit depends on your goals.
| INCY | VYM | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | — |
52-Week High | $118.52 | $161.17 |
52-Week Low | $67.38 | $132.90 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
VYM trades at $159.41, down 0.47% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF holds $94.6 billion in assets, emphasizing high dividend yield from U.S. large-cap stocks. Recent news highlights institutional buying and its role in retirement income strategies, with a dividend of $0.98 scheduled for June 2026.
Outlook remains positive for income-focused investors due to broad diversification and low costs, though risks include interest rate sensitivity and market volatility. The ETF's appeal lies in steady cash flow, but competition from higher-yielding funds poses a challenge to outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
